194 related articles for article (PubMed ID: 17224852)
1. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review.
Peled Y; Perri T; Pardo Y; Kaplan B
Menopause; 2007; 14(3 Pt 1):550-4. PubMed ID: 17224852
[TBL] [Abstract][Full Text] [Related]
2. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment.
Andersson K; Stadberg E; Mattsson LA; Rybo G; Samsioe G
Int J Fertil Menopausal Stud; 1996; 41(5):476-83. PubMed ID: 8934257
[TBL] [Abstract][Full Text] [Related]
3. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
Raudaskoski T; Knip M; Laatikainen T
Menopause; 1998; 5(4):217-22. PubMed ID: 9872487
[TBL] [Abstract][Full Text] [Related]
4. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
Wildemeersch D; Schacht E; Wildemeersch P; Calleweart K; Pylyser K; De Wever N
Maturitas; 2004 May; 48(1):65-70. PubMed ID: 15223110
[TBL] [Abstract][Full Text] [Related]
5. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women.
Sturdee DW; Rantala ML; Colau JC; Zahradnik HP; Riphagen FE;
Climacteric; 2004 Dec; 7(4):404-11. PubMed ID: 15799612
[TBL] [Abstract][Full Text] [Related]
6. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy.
Andersson K; Mattsson LA; Rybo G; Stadberg E
Obstet Gynecol; 1992 Jun; 79(6):963-7. PubMed ID: 1579323
[TBL] [Abstract][Full Text] [Related]
7. Effects of estrogen-progestin replacement therapy on plasma beta-endorphin levels in menopausal women.
Ortega E; Cuadros JL; Gonzalez AR; Ruiz E
Biochem Mol Biol Int; 1993 Apr; 29(5):831-6. PubMed ID: 8508135
[TBL] [Abstract][Full Text] [Related]
8. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
Foidart JM; Faustmann T
Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
[TBL] [Abstract][Full Text] [Related]
9. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
L'hermite M; Simoncini T; Fuller S; Genazzani AR
Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
Kesim MD; Aydin Y; Atis A; Mandiraci G
Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
[TBL] [Abstract][Full Text] [Related]
12. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year.
Wollter-Svensson LO; Stadberg E; Andersson K; Mattsson LA; Odlind V; Persson I
Acta Obstet Gynecol Scand; 1997 May; 76(5):449-54. PubMed ID: 9197448
[TBL] [Abstract][Full Text] [Related]
13. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
[TBL] [Abstract][Full Text] [Related]
14. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy.
Suhonen S; Holmström T; Lähteenmäki P
Acta Obstet Gynecol Scand; 1997 Feb; 76(2):145-50. PubMed ID: 9049288
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a transdermal continuous combined and an interrupted progestogen HRT.
Cameron ST; Glasier AF; Gebbie A; Dewart H; Baird DT
Maturitas; 2006 Jan; 53(1):19-26. PubMed ID: 16325020
[TBL] [Abstract][Full Text] [Related]
16. Routes of delivery for progesterone and progestins.
Sitruk-Ware R
Maturitas; 2007 May; 57(1):77-80. PubMed ID: 17368973
[TBL] [Abstract][Full Text] [Related]
17. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.
Ylikorkala O
Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649
[No Abstract] [Full Text] [Related]
18. Effect of estradiol valerate and levonorgestrel on vaginal health.
Manonai J; Chittacharoen A; Theppisai U
Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):190-3. PubMed ID: 15262354
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel intrauterine device: new preparation. An alternative.
Prescrire Int; 1999 Dec; 8(44):175-7. PubMed ID: 11503815
[TBL] [Abstract][Full Text] [Related]
20. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.
Lundström E; Söderqvist G; Svane G; Azavedo E; Olovsson M; Skoog L; von Schoultz E; von Schoultz B
Fertil Steril; 2006 Apr; 85(4):989-95. PubMed ID: 16580385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
